For research use only · Not for human consumption
This material is reference information for laboratory study of research peptides. It is not medical advice and it is not instructions for human use, self-administration, or therapeutic application. Capital Peptides supplies research chemicals for in-vitro and animal-model study only. Discuss any health-related questions with a licensed medical practitioner.
Most peptide side effects are dose-dependent and temporary. The standard management is: reduce dose, allow adaptation time, or cycle off if persistent.
1. Water retention
Caused by: GH secretagogues. GH stimulates aldosterone and promotes sodium and water retention, particularly in the first 2–4 weeks of a cycle.
Severity: Usually mild — slight puffiness, ring tightness, 1–3 kg of scale weight increase. Significant peripheral oedema is uncommon at typical research doses.
| Severity | Signs | Action |
|---|---|---|
| Mild | Slight face puffiness, rings slightly tight, 1–2 kg scale increase | Usually self-resolves by week 3. Reduce sodium intake. Stay hydrated. |
| Moderate | Noticeable ankle/hand swelling, 2–3 kg scale increase, blood pressure slightly elevated | Consider reducing dose 25–30%. If BP elevated, take seriously. |
| Significant | Pitting oedema, shortness of breath, rapid weight gain >4 kg | Stop the compound. Seek medical review — pitting oedema with dyspnoea needs evaluation. |
2. Nausea (GLP-1 agonists)
Caused by: GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide). GLP-1 receptors are abundant in the GI tract and directly slow gastric emptying, causing nausea — especially when eating too much or too fast.
Management strategies:
- Eat smaller meals, slowly. Large meals are the primary trigger for GLP-1 nausea.
- Avoid high-fat, high-spice, and very sweet foods during the first 2–4 weeks.
- Inject at night before sleep — sleeping through the peak plasma concentration reduces perceived nausea.
- If nausea is severe, reduce dose and titrate up more slowly (over 4 weeks instead of 2).
- Ginger tea, small crackers, or ginger tablets are helpful for mild nausea.
3. Increased hunger (GHRPs)
Caused by: GHRP-2 and GHRP-6 directly stimulate ghrelin (the hunger hormone), causing significant appetite increases. Ipamorelin has minimal ghrelin effect.
Management:
- GHRP hunger peaks ~30–60 minutes post-injection and subsides over 2–3 hours.
- If using GHRP for body composition goals, plan a high-protein meal timed around the hunger window.
- If GHRP hunger is disruptive (eating out of protocol, poor adherence), switch to ipamorelin which lacks the ghrelin-stimulating effect.
- The hunger effect does not diminish much with time — it's an intrinsic property of these compounds, not a sign to push through.
4. Fatigue and lethargy
Caused by: GH pulses (especially the first few weeks), GLP-1 dose escalation, or any peptide if timing interferes with sleep cycles.
Management:
- GH-related fatigue: typically occurs 30–90 minutes post-injection. Dose pre-bed to avoid impairment during the day.
- If fatiguing during daytime doses, shift to evening-only dosing temporarily.
- Ensure you're not under-eating — GH secretagogues in a severe caloric deficit can cause pronounced fatigue.
- Persistent unexplained fatigue after 4 weeks warrants bloodwork — thyroid function and cortisol in particular.
5. Injection-site reactions
| Reaction | Likely cause | Management |
|---|---|---|
| Small red bump resolving in 1–2 hours | Normal inflammatory response to needle puncture | No action needed |
| Bruising | Nicked capillary / injecting too fast | Apply gentle pressure; no rubbing; slow injection next time |
| Persistent lump (days) | Lipohypertrophy (fat thickening) | Rotate sites more aggressively; don't inject same spot within 5 days |
| Redness spreading beyond site, warm | Possible early infection | Stop using that vial; clean the site; watch closely. If spreading: see a doctor. |
| Itching at site | Mild allergic reaction to excipient or compound | Usually resolves. If spreading or systemic: stop and seek advice. |
| Significant swelling + fever | Infection — possible vial contamination | Stop using vial. Seek medical attention. |
6. Headache
Caused by: GH-axis peptides (from GH-stimulated fluid shifts), dehydration, or rapid dose escalation.
- Drink adequate water — GH-axis peptides increase fluid retention but also increase the body's fluid demands.
- Headaches that appear consistently post-injection usually resolve within 1–2 weeks as adaptation occurs.
- If headache is severe, throbbing, or accompanied by visual changes — stop the compound. This is distinct from mild adaptation headache.
7. Flushing and tingling
Caused by: GH release, PT-141 (bremelanotide), or GHRP compounds. GH release causes peripheral vasodilation — warmth, flushing, and tingling especially in the face and extremities.
This is expected and harmless at normal research doses. It peaks ~30 minutes post-injection and resolves within 1–2 hours. If severe or prolonged, reduce dose.
8. Carpal tunnel symptoms
Caused by: GH elevation — GH and IGF-1 can cause fluid accumulation in the carpal tunnel, compressing the median nerve. Numbness, tingling, or weakness in the hand and fingers.
- More common in those who already have some carpal tunnel narrowing, or with high doses / long cycles.
- Management: reduce dose, add wrist stretching, consider a wrist brace at night.
- Resolves on stopping the GH secretagogue — it's not permanent nerve damage in most cases.
- If symptoms are severe or bilateral, reduce dose immediately and consult a doctor.